- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- 【Updated on June 30, 2025】Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Prospective comparison of the effects of maxacalcitol and of intravenous calcitriol on secondary hyperparathyroidism in chronic hemodialysis patients
-
- Ando Ryoichi
- Department of Medicine, Nakano General Hospital
-
- Yoshikawa Momono
- Department of Medicine, Nakano General Hospital
-
- Yamashita Yumi
- Department of Medicine, Nakano General Hospital
-
- Doi Mayumi
- Department of Medicine, Nakano General Hospital
-
- Chida Yoshiko
- Department of Medicine, Nakano General Hospital
-
- Ida Takashi
- Department of Medicine, Nakano General Hospital
-
- Ishida Yuji
- Kyonan Clinic
-
- Akiba Takashi
- Division of Blood Purification, Kidney Center, Tokyo Woman's Medical University
Bibliographic Information
- Other Title
-
- 血液透析患者におけるマキサカルシトール,静注カルシトリオールの二次性副甲状腺機能こう進症に対する効果比較
Search this article
Description
To compare the effect of maxacalcitol and of intravenous calcitriol on secondary hyperparathyroidism, we conducted a 24-week prospective study for 20 chronic hemodialysis patients. Five or ten μg of maxacalcitol (5μg for patients with intact parathyroid hormone (PTH) less than 500pg/mL and 10μg for those with intact PTH higher than 500pg/mL) was administered intravenously to 10 patients, and 0.5 or 1.0μg of calcitriol (0.5μg for patients with intact PTH less than 500pg/mL and 1.0μg for those with intact PTH higher than 500pg/mL) was administered intravenously to 10 patients, at the end of every hemodialysis session. Dosage was changed according to PTH and serum calcium. We compared whole PTH, a new immunoradiometric assay exclusively for biologically active PTH (1-84), carboxy-terminal fragment (7-84) of PTH, intact PTH, bone-specific alkaline phosphatase (BAP), intact osteocalcin (iOC), amino-terminal propeptide of type I procollagen (PINP), serum calcium ajusted for albumin (Ca) and phosphorus (P).<br>Both maxacalcitol and calcitriol suppressed whole PTH 4 weeks after the start of administration. Calcitriol had less suppressing effect on whole PTH from 8 to 12 weeks of the study. From 16 to 24 weeks of the study, maxacalcitol and calcitriol showed almost equal whole PTH-suppressing effects. Intact PTH, 7-84 PTH, BAP, iOC and PINP showed almost similar changes as in whole PTH. However, the changes in BAP, iOC and PINP in patients treated with calcitriol were comparable. Ca increased and P showed no significant change. At the end of the study, there was no significant difference in these parameters between maxacalcitol and calcitriol. The effect of maxacalcitol was found to be 7 times higher than that of calcitriol.<br>In conclusion, maxacalcitol and calcitriol had almost equal effects on PTH, calcium and phosphorus, if dosages of these drugs are adjusted. The efficacy ratio of maxacalcitol to calcitriol was considered about 1:7.
Journal
-
- Nihon Toseki Igakkai Zasshi
-
Nihon Toseki Igakkai Zasshi 36 (5), 317-325, 2003
The Japanese Society for Dialysis Therapy
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390282679653836544
-
- NII Article ID
- 130003721702
-
- ISSN
- 1883082X
- 13403451
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- Crossref
- CiNii Articles
-
- Abstract License Flag
- Disallowed